Yasar Torres‐Yaghi

990 total citations
29 papers, 640 citations indexed

About

Yasar Torres‐Yaghi is a scholar working on Neurology, Hematology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Yasar Torres‐Yaghi has authored 29 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Neurology, 9 papers in Hematology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Yasar Torres‐Yaghi's work include Parkinson's Disease Mechanisms and Treatments (16 papers), Neurological disorders and treatments (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Yasar Torres‐Yaghi is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (16 papers), Neurological disorders and treatments (12 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Yasar Torres‐Yaghi collaborates with scholars based in United States, Japan and Italy. Yasar Torres‐Yaghi's co-authors include Fernando Pagán, Michaeline Hebron, Jaeil Ahn, Charbel Moussa, Barbara Wilmarth, Abigail Lawler, Sara Matar, Elizabeth Mundel, Nadia Yusuf and Xu Huang and has published in prestigious journals such as Neurology, Annals of Neurology and Human Molecular Genetics.

In The Last Decade

Yasar Torres‐Yaghi

27 papers receiving 625 citations

Peers

Yasar Torres‐Yaghi
Abigail Lawler United States
Barbara Wilmarth United States
Aaron Carlson United States
Sruti Rayaprolu United States
I. Moroo Japan
Jiacheng Ma United States
Abigail Lawler United States
Yasar Torres‐Yaghi
Citations per year, relative to Yasar Torres‐Yaghi Yasar Torres‐Yaghi (= 1×) peers Abigail Lawler

Countries citing papers authored by Yasar Torres‐Yaghi

Since Specialization
Citations

This map shows the geographic impact of Yasar Torres‐Yaghi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasar Torres‐Yaghi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasar Torres‐Yaghi more than expected).

Fields of papers citing papers by Yasar Torres‐Yaghi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasar Torres‐Yaghi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasar Torres‐Yaghi. The network helps show where Yasar Torres‐Yaghi may publish in the future.

Co-authorship network of co-authors of Yasar Torres‐Yaghi

This figure shows the co-authorship network connecting the top 25 collaborators of Yasar Torres‐Yaghi. A scholar is included among the top collaborators of Yasar Torres‐Yaghi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasar Torres‐Yaghi. Yasar Torres‐Yaghi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Hauser, Robert A., Yasar Torres‐Yaghi, Stanley E. Fisher, & Ghazal Banisadr. (2025). How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 13. 100357–100357.
3.
Pagán, Fernando, Yasar Torres‐Yaghi, Michaeline Hebron, et al.. (2025). Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib. Journal of Clinical Medicine. 14(12). 4245–4245. 1 indexed citations
4.
Pagán, Fernando, Paul E. Schulz, Yasar Torres‐Yaghi, & Gregory M. Pontone. (2024). On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis. CNS Drugs. 38(5). 333–347. 4 indexed citations
5.
Isaacson, Stuart, Daniel Kremens, Yasar Torres‐Yaghi, Fabrizio Stocchi, & Angelo Antonini. (2023). Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's disease. Parkinsonism & Related Disorders. 114. 105495–105495. 4 indexed citations
6.
Torres‐Yaghi, Yasar, Nobutaka Hattori, Olivier Rascol, et al.. (2023). Istradefylline effects on tremor dominance (TD) and postural instability and gait difficulty (PIGD). Clinical Parkinsonism & Related Disorders. 9. 100224–100224. 3 indexed citations
7.
Torres‐Yaghi, Yasar, et al.. (2023). Adenosine A2A antagonists and Parkinson’s disease. International review of neurobiology. 170. 105–119. 3 indexed citations
8.
Torres‐Yaghi, Yasar, et al.. (2022). Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic. Telemedicine Journal and e-Health. 28(11). 1651–1657. 1 indexed citations
9.
Pahwa, Rajesh, Stuart Isaacson, Gary W. Small, et al.. (2022). Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel. Neurology and Therapy. 11(4). 1571–1582. 4 indexed citations
10.
Sabbagh, Marwan N., Gary W. Small, Stuart Isaacson, et al.. (2022). Unmet needs in the diagnosis and treatment of Parkinson’s disease psychosis and dementia-related psychosis. International Journal of Psychiatry in Clinical Practice. 27(1). 69–81. 3 indexed citations
11.
Torres‐Yaghi, Yasar, et al.. (2021). QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review. Dove Medical Press (Taylor and Francis Group). 10 indexed citations
12.
Pagán, Fernando, Yasar Torres‐Yaghi, Michaeline Hebron, Jaeil Ahn, & Charbel Moussa. (2021). Long-term Safety and Clinical Effects of Nilotinib in Parkinson’s Disease (4799). Neurology. 96(15_supplement). 1 indexed citations
13.
Fayed, Islam, Yasar Torres‐Yaghi, Fernando Pagán, et al.. (2021). Combination targeting of subthalamic nucleus and ventral intermediate thalamic nucleus with a single trajectory in deep brain stimulation for tremor-dominant Parkinson’s disease. Journal of Clinical Neuroscience. 85. 92–100. 6 indexed citations
14.
Pagán, Fernando, et al.. (2021). Istradefylline Effects on Tremor Dominant (TD) and Postural Instability and Gait Difficulty (PIGD) Motor Subtypes (4540). Neurology. 96(15_supplement). 1 indexed citations
15.
Fowler, Alan J., Michaeline Hebron, Yasar Torres‐Yaghi, et al.. (2020). A novel small molecule tyrosine kinase inhibitor (GUtinib) preferentially targets discoidin domain receptors and reduces toxic proteins in neurodegeneration (5398). Neurology. 94(15_supplement). 1 indexed citations
16.
Pagán, Fernando, Michaeline Hebron, Barbara Wilmarth, et al.. (2019). Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. Pharmacology Research & Perspectives. 7(2). e00470–e00470. 73 indexed citations
17.
Pagán, Fernando, et al.. (2017). The diagnosis and natural history of Huntington disease. Handbook of clinical neurology. 144. 63–67. 10 indexed citations
18.
Pagán, Fernando, Yasar Torres‐Yaghi, Michaeline Hebron, et al.. (2016). Nilotinib Improves Motor Skills, Cognition and Autonomic Function in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia (I1.008). Neurology. 86(16_supplement). 1 indexed citations
19.
Pagán, Fernando, Michaeline Hebron, Yasar Torres‐Yaghi, et al.. (2016). Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies. Journal of Parkinson s Disease. 6(3). 503–517. 193 indexed citations
20.
Torres‐Yaghi, Yasar, et al.. (2015). Cardiac Cephalgia. Current Pain and Headache Reports. 19(4). 14–14. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026